Saturday, March 09, 2019 1:30:29 AM
GlobeNewswire•March 6, 2019
ALAMEDA, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, CEO of OncoCyte Corporation, will be presenting at the Cowen and Company 39th Annual Health Care Conference, taking place March 11-13 at the Boston Marriott Copley Place hotel in Boston, Massachusetts.
Cowen and Company 39th Annual Health Care Conference
Date: Wednesday, March 13
Time: 10:00am Eastern Time
Location: Boston Marriott Copley Place
Webcast: http://wsw.com/webcast/cowen52/ocx/
About OncoCyte Corporation
OncoCyte is focused on the development and commercialization of novel, non-invasive blood (“liquid biopsy”) diagnostic tests for the early detection of cancer. Early detection of cancer can improve health outcomes, reduce the cost of care, and improve patients’ quality of life. Liquid biopsy diagnostic tests like those OncoCyte is developing may reduce the need for costlier and riskier diagnostic procedures such as invasive biopsy procedures. OncoCyte’s is focusing its efforts on developing DetermaVu™ as a non-invasive confirmatory diagnostic test for lung cancer. DetermaVu™ is being developed using proprietary sets of genetic and protein molecular markers to detect the presence of lung cancer. OncoCyte also plans to conduct research to identify additional molecular markers, acquire or license markers and related technology, and develop tests for additional types of cancer based on those markers.
Investor Contacts
Bob Yedid
LifeSci Advisors, LLC
bob@lifesciadvisors.com
646-597-6989
Media Contact
Andrew Mielach
LifeSci Public Relations
amielach@lifescipublicrelations.com
646-876-5868
https://finance.yahoo.com/news/oncocyte-corporation-present-cowen-company-211500563.html
GO OCX
"PEACE"
Recent OCX News
- Oncocyte Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/12/2024 10:00:00 AM
- Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/12/2024 01:46:37 AM
- Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay • GlobeNewswire Inc. • 04/11/2024 09:30:00 PM
- Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 04/09/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:39:38 PM
- Oncocyte to Present at the Sequire Investor Summit in Puerto Rico • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays • GlobeNewswire Inc. • 12/06/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:19:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:05:24 PM
- Oncocyte Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/09/2023 12:00:00 PM
- Oncocyte to Announce Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/03/2023 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/12/2023 08:30:57 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 10/10/2023 08:48:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:05:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 01:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 08:05:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2023 10:57:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:50:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 11:05:36 AM
- VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients • GlobeNewswire Inc. • 07/25/2023 01:08:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 09:28:38 PM
- Oncocyte Announces 1-For-20 Reverse Stock Split • GlobeNewswire Inc. • 07/24/2023 05:35:32 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/21/2023 09:16:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/14/2023 10:03:15 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/10/2023 03:20:07 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM